Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01211717 · ClinicalTrials.gov registry record · NA

The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients

A NA study of Type 2 Diabetes and Healthy Individuals, sponsored by Loma Linda University.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT01211717 is a NA study of Type 2 Diabetes and Healthy Individuals that has completed, run by Loma Linda University. The registered enrollment target is 50 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01211717, a NA study of Type 2 Diabetes and Healthy Individuals, has completed, sponsored by Loma Linda University.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effectiveness of the 3 Branched Chained Amino Acids (isoleucine, leucine, and valine) on treating Delayed Onset Muscle Soreness, a type of muscle pain which usually develops after exercising.

Interventions

  • DIETARY_SUPPLEMENT Branched Chained Amino Acids
  • OTHER Cellulose Placebo mix

Study Locations (1)

California

  • Loma Linda University, School of Allied Health Professions - Loma Linda

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2010-10
Est. Completion 2011-04
Phase NA

Sponsor

Loma Linda University

237 total trials

What the Registry Record Tells You About NCT01211717

The ClinicalTrials.gov registry entry for NCT01211717 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (95% lower). The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Branched Chained Amino Acids is the first listed.

NCT01211717 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01211717 about?

NCT01211717 is a clinical study titled "The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients". The purpose of this study is to determine the effectiveness of the 3 Branched Chained Amino Acids (isoleucine, leucine, and valine) on treating Delayed Onset Muscle Soreness, a type of muscle pain which usually develops after exercising.

What is the current status of trial NCT01211717?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2010-10. Estimated completion is 2011-04.

What conditions does trial NCT01211717 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Healthy Individuals.

What interventions are being tested in trial NCT01211717?

The interventions under investigation include: Branched Chained Amino Acids (DIETARY_SUPPLEMENT), Cellulose Placebo mix (OTHER).

Who is sponsoring clinical trial NCT01211717?

This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01211717 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.